Tag : BREAST CANCER

The phase 3 OPTIMA trial demonstrated that Prosigna-guided test-directed therapy achieved noninferior invasive breast cancer-free survival (IBCFS) vs. standard chemo-endocrine therapy in high-clinical-risk ER+/HER2-negative early breast cancer (eBC), supporting the use of multigene expression assays to inform individualized adjuvant chemotherapy decisions.

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer is the most prevalent subtype of the disease, accounting for approximately 70% of all cases. While first-line endocrine-based regimens demonstrate considerable efficacy, later-line single-agent chemotherapy has limited effectiveness, highlighting a significant unmet need.